Introduction: Tendon injuries can be categorized into acute or chronic and result in significant pain and loss of tendon function. The recovery of tendon damage is a complex and time-consuming recovery process. Tendon injuries produce considerable morbidity and cause disability for several months despite appropriate management. Nutritional interventions, e.g. intake of collagen, are a plausible, potential strategy to improve the prevention and healing of tendinopathy. Adequate intake of nutrients – macronutrients as well as micronutrients – is of great importance. Hence, the test product Tendoshot Pro tablet which is a synergistic blend of Protein hydrosylate, Marine collagen peptide, Chondroitin, Vitamin C, Vitamin D3, Vitamin B6, Vitamin B12, Magnesium, Zinc, Nano curcumin, Sodium hyaluronate, Manganese is evaluated in this study.

Aim: This study was designed as a single-arm, interventional case study aimed at evaluating the efficacy, safety and tolerability of Tendoshot Pro in Tendon Injury patients.

Materials and methods:  Thirty adult patients with grade 2 tendon injuries of the knee, ankle, or shoulder were enrolled based on predefined inclusion and exclusion criteria. Participants received Tendoshot Pro (one tablet twice daily) alongside standard care for 12 weeks. Clinical assessments - including VAS pain scores, Activity Limitation Scale (MLQoL), ESR, hs-CRP, Global Rating of Change, SF-12 quality-of-life scores, and MRI imaging—were conducted at baseline and follow-up visits at weeks 4, 8, and 12. Safety was monitored through adverse event reporting and laboratory evaluations. Statistical analysis was performed using SPSS v21.0 with appropriate parametric and non-parametric tests. Participants were monitored throughout the study to evaluate primary and secondary outcome measures.

Results: VAS pain scores significantly decreased from 6.6 ± 1.8 at baseline to 3.06 ± 0.89 at week 12 (p < 0.001). ESR and hs-CRP levels showed marked reductions, indicating systemic anti-inflammatory effects. 73% of patients returned to pre-injury activity levels by week 12. SF-12 scores improved across physical and emotional domains, and MRI imaging confirmed tissue recovery. Mild gastrointestinal side effects were reported in 3 patients, with no serious adverse events.